Kura Oncology, Inc.
KURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422143
In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 8 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:14 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $278.7M (412.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Jan 30, 2024 | Jan 9, 2023 | Feb 24, 2022 |
| Revenue | $67.5M | $53.9M | – | – | – |
| Operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M |
| Research and development | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M |
| Selling, general and administrative | $120.0M | $77.1M | $50.6M | $47.1M | $46.5M |
| Operating income | -$303.6M | -$193.2M | – | – | – |
| Interest expense | – | – | $1.55M | $229.0K | $414.0K |
| Income tax | $297.0K | $2.02M | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M |
| EPS, basic | $-3.18 | $-2.02 | $-2.08 | $-2.03 | – |
| EPS, diluted | $-3.18 | $-2.02 | $-2.08 | $-2.03 | – |
| Weighted shares, basic | 87.7M | 86.2M | 73.2M | 67.0M | – |
| Weighted shares, diluted | 87.7M | 86.2M | 73.2M | 67.0M | – |
| Margins and growth | |||||
| Operating margin | -449.9% | -358.5% | – | – | – |
| Net margin | -412.9% | -322.9% | – | – | – |
| Revenue growth, year over year | +25.2% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Jan 30, 2024 | Jan 9, 2023 | Feb 24, 2022 |
| Cash and equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M |
| Accounts receivable | $8.80M | – | – | – | – |
| Inventory | $413.0K | – | – | – | – |
| Total current assets | $708.7M | $744.8M | $432.5M | $446.4M | $522.3M |
| Property, plant and equipment | $7.86M | $1.68M | $1.86M | $2.54M | $2.67M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Accounts payable | $5.02M | $1.47M | $2.30M | $1.53M | $3.24M |
| Short-term debt | $0 | $2.61M | – | – | – |
| Total current liabilities | $117.0M | $78.7M | $35.3M | $24.1M | $22.5M |
| Long-term debt | $9.71M | $6.92M | $9.33M | $9.16M | – |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
| Shareholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 26, 2025 | Jan 30, 2024 | Jan 9, 2023 | Feb 24, 2022 |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Capital expenditures | $6.64M | $472.0K | $168.0K | $626.0K | $1.15M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M |
| Stock-based compensation | $37.1M | $33.9M | $28.1M | $26.3M | $23.6M |
| Investing cash flow | -$13.1M | -$101.6M | $15.6M | $32.6M | -$126.8M |
| Financing cash flow | $1.79M | $154.4M | $94.8M | $38.6M | -$3.44M |
| Net change in cash | -$75.4M | $187.1M | -$14.5M | -$38.9M | -$234.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 55.0% | 62.9% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 91.9M | +5.6% | SEC |
| Aug 7, 2026 | 89.0M | +2.5% | SEC |
| May 8, 2026 | 88.8M | +2.5% | SEC |
| Feb 27, 2026 | 88.3M | +9.4% | SEC |
| Oct 31, 2025 | 87.0M | +11.9% | SEC |
| Aug 1, 2025 | 86.8M | +13.3% | SEC |
| Apr 28, 2025 | 86.6M | +13.6% | SEC |
| Feb 20, 2025 | 80.8M | +6.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.